Measuring therapeutic efficacy in patients with Alzheimer's disease: Role of instruments

Dementia and Geriatric Cognitive Disorders

Volumn 31, Issue 3, 2011, Pages 233-238

  Riepe, Matthias W ^a   Janetzky, Wolfgang ^b   Lemming, Ole M ^c  

^a UNIVERSITY OF ULM   (Germany)

^b Lundbeck GmbH   (Germany)

^c H LUNDBECK A S   (Denmark)

Author keywords

Alzheimer's disease; Cognition; Effect size; Meta analysis

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ANALYSIS OF COVARIANCE; ARTICLE; COGNITION; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; EFFECT SIZE; HUMAN; LANGUAGE; MEMORY; META ANALYSIS; MINI MENTAL STATE EXAMINATION; ORIENTATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; SEVERE IMPAIRMENT BATTERY; THERAPY EFFECT;

ALZHEIMER DISEASE; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; META-ANALYSIS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79953729991     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000326214     Document Type: Article

References (26)

1. Areosa SA, Sherriff F: Memantine for dementia. Cochrane Database Syst Rev 2003;CD003154.
2. Ashford JW, Kolm P, Colliver JA, Bekian C, Hsu LN: Alzheimer patient evaluation and the mini-mental state: item characteristic curve analysis. J Gerontol 1989; 44: 139-146.
3. Benge JF, Balsis S, Geraci L, Massman PJ, Doody RS: How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimers disease? Dement Geriatr Cogn Disord 2009; 28: 63-69.
4. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V: The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997; 337: 1667-1674. (Pubitemid 27510105)
5. Feldman HH, Schmitt FA, Olin JT: Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006; 20: 263-268. (Pubitemid 44900940)
6. Folstein MF, Folstein SE, McHugh PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
7. Folstein MF, Robins LN, Helzer JE: The Mini-Mental State Examination. Arch Gen Psychiatry 1983; 40: 812.
8. Godefroy O, Cabaret M, Petit-Chenal V, Pruvo JP, Rousseaux M: Control functions of the frontal lobes: modularity of the centralsupervisory system? Cortex 1999; 35: 1-20. (Pubitemid 29123818)
9. Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW: Subjective memory complaints: objective neural markers in patients with Alzheimers disease and major depressive disorder. Ann Neurol 2002; 51: 491-498. (Pubitemid 34260779)
10. Gron G, Riepe MW: A neural basis of the cognitive continuum in episodic memory from health to Alzheimers disease. Am J Geriatr Psychiatry 2004; 12: 648-652. (Pubitemid 41031067)
11. Hodges JR: Memory in the dementias; in Tulving E, Craik FIM (eds): The Oxford Handbook of Memory. Oxford, Oxford University Press, 2000, pp 441-459.
12. Hyman BT, Van Horsen GW, Damasio AR, Barnes CL: Alzheimers disease: cell-specific pathology isolates the hippocampal formation. Science 1984; 225: 1168-1170. (Pubitemid 14029099)
13. Marshall JC, Fink GR: Spatial cognition: where we were and where we are. Neuroimage 2001; 14:S2-S7. (Pubitemid 32554523)
14. McShane R, Areosa SA, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006; CD003154
15. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA: Modelling mini mental state examination changes in Alzheimers disease. Stat Med 2000; 19: 1607-1616. (Pubitemid 30346250)
16. Nagahama Y, Okada T, Katsumi Y, Hayashi T, Yamauchi H, Oyanagi C, Konishi J, Fukuyama H, Shibasaki H: Dissociable mechanisms of attentional control within the human prefrontal cortex. Cereb Cortex 2001; 11: 85-92. (Pubitemid 32064178)
17. Panisset M, Roudier M, Saxton J, Boller F: Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol 1994; 51: 41-45. (Pubitemid 24020169)
18. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT: Memantine treatment in patients with mild to moderate Alzheimers disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5: 83-89. (Pubitemid 351536358)
19. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate- to-severe Alzheimers disease. N Engl J Med 2003; 348: 1333-1341. (Pubitemid 36384100)
20. Rive B, Vercelletto M, Damier FD, Cochran J, Francois C: Memantine enhances autonomy in moderate to severe Alzheimers disease. Int J Geriatr Psychiatry 2004; 19: 458-464. (Pubitemid 38697039)
21. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimers disease. Am J Psychiatry 1984; 141: 1356-1364.
22. Rowe JB, Toni I, Josephs O, Frackowiak RS, Passingham RE: The prefrontal cortex: response selection or maintenance within working memory? Science 2000; 288: 1656-1660. (Pubitemid 30387434)
23. Save E, Poucet B: Hippocampal-parietal cortical interactions in spatial cognition. Hippocampus 2000; 10: 491-499.
24. Saxton J, Swihart AA: Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med 1989; 5: 531-543. (Pubitemid 19207868)
25. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324. (Pubitemid 38101604)
26. Winblad B, Poritis N: Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-146. (Pubitemid 29110331)